EP3102206A4 - Combinations of ikk /tbk1 inhibitors with beta adrenergic agonists or sympathetic nervous system activators - Google Patents

Combinations of ikk /tbk1 inhibitors with beta adrenergic agonists or sympathetic nervous system activators Download PDF

Info

Publication number
EP3102206A4
EP3102206A4 EP14881460.1A EP14881460A EP3102206A4 EP 3102206 A4 EP3102206 A4 EP 3102206A4 EP 14881460 A EP14881460 A EP 14881460A EP 3102206 A4 EP3102206 A4 EP 3102206A4
Authority
EP
European Patent Office
Prior art keywords
ikk
combinations
nervous system
sympathetic nervous
adrenergic agonists
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP14881460.1A
Other languages
German (de)
French (fr)
Other versions
EP3102206A1 (en
Inventor
Alan R. Saltiel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Michigan
Original Assignee
University of Michigan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Michigan filed Critical University of Michigan
Publication of EP3102206A1 publication Critical patent/EP3102206A1/en
Publication of EP3102206A4 publication Critical patent/EP3102206A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EP14881460.1A 2014-02-07 2014-02-07 Combinations of ikk /tbk1 inhibitors with beta adrenergic agonists or sympathetic nervous system activators Withdrawn EP3102206A4 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2014/015387 WO2015119624A1 (en) 2014-02-07 2014-02-07 COMBINATIONS OF IKKε/TBK1 INHIBITORS WITH BETA ADRENERGIC AGONISTS OR SYMPATHETIC NERVOUS SYSTEM ACTIVATORS

Publications (2)

Publication Number Publication Date
EP3102206A1 EP3102206A1 (en) 2016-12-14
EP3102206A4 true EP3102206A4 (en) 2017-09-20

Family

ID=53778306

Family Applications (1)

Application Number Title Priority Date Filing Date
EP14881460.1A Withdrawn EP3102206A4 (en) 2014-02-07 2014-02-07 Combinations of ikk /tbk1 inhibitors with beta adrenergic agonists or sympathetic nervous system activators

Country Status (6)

Country Link
EP (1) EP3102206A4 (en)
JP (1) JP2017507930A (en)
CN (1) CN106132413A (en)
AU (1) AU2014381711A1 (en)
CA (1) CA2938126A1 (en)
WO (1) WO2015119624A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2659763T3 (en) 2011-02-14 2018-03-19 The Regents Of The University Of Michigan Compositions and procedures for the treatment of obesity and related disorders
EP2991647B1 (en) 2013-05-02 2019-04-24 The Regents Of The University Of Michigan Deuterated amlexanox with improved metabolic stability
US10214536B2 (en) 2016-01-29 2019-02-26 The Regents Of The University Of Michigan Amlexanox analogs
JP7152051B2 (en) * 2018-05-29 2022-10-12 株式会社ナノエッグ Composition for treating or preventing atopic dermatitis

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010139985A1 (en) * 2009-06-01 2010-12-09 Biocopea Limited The use of amlexanox in the therapy of neutrophil-driven diseases

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4525359A (en) * 1982-12-10 1985-06-25 Greenway Frank L Iii Treatment for selective weight control
GB2356197A (en) * 1999-10-12 2001-05-16 Merck & Co Inc Amide derivatives as beta 3 agonists
US20060094682A1 (en) * 2004-10-29 2006-05-04 Odyssey Thera, Inc. Kinase inhibitors for the treatment of diabetes and obesity
US20100009934A1 (en) * 2008-06-09 2010-01-14 Combinatorx, Incorporated Beta adrenergic receptor agonists for the treatment of b-cell proliferative disorders
WO2012016930A1 (en) * 2010-08-05 2012-02-09 Universite De Droit Et Sante De Lille Compound useful for the treatment of nonsense-mutation-mediated diseases and pharmaceutical composition comprising said compound
ES2659763T3 (en) * 2011-02-14 2018-03-19 The Regents Of The University Of Michigan Compositions and procedures for the treatment of obesity and related disorders

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010139985A1 (en) * 2009-06-01 2010-12-09 Biocopea Limited The use of amlexanox in the therapy of neutrophil-driven diseases

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
J. G. KANG ET AL: "Randomized controlled trial to investigate the effects of a newly developed formulation of phentermine diffuse-controlled release for obesity", DIABETES, OBESITY AND METABOLISM, vol. 12, no. 10, 29 October 2010 (2010-10-29), pages 876 - 882, XP055337209, ISSN: 1462-8902, DOI: 10.1111/j.1463-1326.2010.01242.x *
JONATHAN MOWERS ET AL: "Inflammation produces catecholamine resistance in obesity via activation of PDE3B by the protein kinases IKK[epsilon] and TBK1", ELIFE, vol. 2, 24 December 2013 (2013-12-24), pages e01119 - 1, XP055219656, DOI: 10.7554/eLife.01119 *
See also references of WO2015119624A1 *

Also Published As

Publication number Publication date
AU2014381711A1 (en) 2016-08-18
JP2017507930A (en) 2017-03-23
CN106132413A (en) 2016-11-16
CA2938126A1 (en) 2015-08-13
WO2015119624A1 (en) 2015-08-13
EP3102206A1 (en) 2016-12-14

Similar Documents

Publication Publication Date Title
HK1246794A1 (en) Bicyclic heterocycles as fgfr inhibitors
IL253869B (en) Bicyclic heterocycles as fgfr4 inhibitors
HK1253727A1 (en) Methods of using pyruvate kinase activators
IL251932B (en) Benzylpropargylether as nitrification inhibitors
GB201421088D0 (en) New enzyme inhibitors
ZA201608165B (en) Low-viscosity lubricating polyolefins
GB201421085D0 (en) New enzyme inhibitors
SG11201708288SA (en) Processes for reducing the fouling of surfaces
HK1246184A1 (en) Aminobenzisoxazole compounds as agonists of a7-nicotinic acetylcholine receptors
RS63203B1 (en) Compounds useful as ripk1 inhibitors
AU2016250786B2 (en) Centerfill of lubricant reservoir
EP3353170A4 (en) New benzimidazoles derivatives as tec kinases family inhibitors
EP3102206A4 (en) Combinations of ikk /tbk1 inhibitors with beta adrenergic agonists or sympathetic nervous system activators
SG10201603626RA (en) Methods for increasing the rate of electrochemical deposition
EP3194640A4 (en) Additives for electrodeposition
SG11201609152XA (en) Anti-corrosion additives
GB201417529D0 (en) Beta lactamase inhibitors
IL264406B (en) Combination of histamine-3 receptor inverse agonists with acetylcholinesterase inhibitors
HK1253295A1 (en) Geminal substituted aminobenzisoxazole compounds as agonists of 7-nicotinic acetylcholine receptors
EP3130209A4 (en) Liquid coolant supply

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20160907

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20170818

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/4184 20060101ALI20170811BHEP

Ipc: A61K 31/436 20060101AFI20170811BHEP

Ipc: A61P 1/16 20060101ALI20170811BHEP

Ipc: A61K 45/06 20060101ALI20170811BHEP

Ipc: A61P 3/04 20060101ALI20170811BHEP

Ipc: A61P 3/10 20060101ALI20170811BHEP

Ipc: A61K 31/137 20060101ALI20170811BHEP

Ipc: A61K 31/36 20060101ALI20170811BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20180316